KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Research & Development (2016 - 2026)

Pacira BioSciences has reported Research & Development over the past 17 years, most recently at $28.1 million for Q1 2026.

  • For Q1 2026, Research & Development rose 10.77% year-over-year to $28.1 million; the TTM value through Mar 2026 reached $119.7 million, up 34.97%, while the annual FY2025 figure was $117.3 million, 43.81% up from the prior year.
  • Research & Development for Q1 2026 was $28.1 million at Pacira BioSciences, down from $37.5 million in the prior quarter.
  • Over five years, Research & Development peaked at $37.5 million in Q4 2025 and troughed at $17.1 million in Q1 2023.
  • A 5-year average of $22.8 million and a median of $20.8 million in 2023 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 109.04% in 2022 and later dropped 28.38% in 2023.
  • Year by year, Research & Development stood at $17.5 million in 2022, then increased by 11.19% to $19.5 million in 2023, then grew by 22.78% to $23.9 million in 2024, then skyrocketed by 56.73% to $37.5 million in 2025, then fell by 25.05% to $28.1 million in 2026.
  • Business Quant data shows Research & Development for PCRX at $28.1 million in Q1 2026, $37.5 million in Q4 2025, and $26.0 million in Q3 2025.